Find an expert
We have many medical experts who can give opinions and guidance on health stories. Search or browse our list of experts by areas of expertise or name.
Expert Areas of expertise
Helen Ackland is the Senior Clinical Trauma Research Fellow at The Alfred, and works collaboratively with the departments of Intensive Care, Radiology, Emergency, Trauma, Orthopaedics and Neurosurgery.
Her primary areas of interest include cervical spine injury investigation, spinal imaging and ladder fall-related injuries and prevention.
Mr Frank Bruscino-Raiola graduated from Monash University in 1991 and completed his fellowship in Plastics and Reconstructive surgery in 2002.
He has been a member of the Victorian Melanoma Service since 2003.
Mr Frank Bruscino-Raiola brings a great volume of experience in melanoma surgery. Apart from his interest in melanoma, he is the head of plastic research at The Alfred.
He is the prime surgeon of the Osseointegration & TMR programme and is also heavily involved in the head and neck, and trauma-related reconstructive surgery.
Prof Cheng works as an infectious diseases physician. His key interests are in influenza, antibiotic resistance and hospital-acquired infections.
He is involved in influenza surveillance in Australian hospitals as well as clinical trials in infectious diseases.
Prof Cheng also has an appointment in the School of Public Health and Preventive Medicine at Monash University.
Heather Cleland is a Plastic Surgeon and currently Head of the Victorian Adult Burns Unit at The Alfred.
She is a member of the Australian Society of Plastic Surgeons, and the Australian and New Zealand Burn Association, of which she is a Past President and current board member. She chairs the Board Burns Quality Improvement Program Committee, and is Chair of the Steering Committee of the Burns Registry of Australia and New Zealand.
She is a member various committees and organizations, including the Court of Examiners of the Royal Australasian College of Surgeons (Plastic Surgery), the Australasian Foundation for Plastic Surgery’s Education Committee, and the Donor Tissue Bank Committee of the Victorian Institute of Forensic Medicine.
She is a member of the Editorial Board of the Journal of the International Society for Burn Injuries (Burns), a reviewer for several international surgical journals, a supervisor for higher degree students, and has published over 100 articles in peer reviewed journals.
Prof Anthony Dart is a clinician specialising in Lipid disorders.
He completed his undergraduate and early postgraduate training at the University of Oxford. He completed a BA (physiology) and DPhil (neurophysiology) prior to completing his medical studies (BM BCh). Following internships in Oxford and Bath, he completed basic physician training in South Wales including posts at Morriston Hospital, Swansea and Llandough, Royal Infirmary and Heath Hospital, Cardiff. He was cardiology registrar at the Heath Hospital (University of Wales). Subsequent appointments were as senior registrar in Aberdeen (Forresterhill Hospital and Aberdeen Royal Infirmary) and Lecturer in the Cardiovascular Research Unit, University of Edinburgh.
He received specialist accreditation in General Medicine, Clinical Pharmacology and Cardiovascular Medicine. He also spent 2 years in the Department of Cardiology, Heidelberg, Germany as a Royal Society European Exchange Fellow. Professor Dart relocated to Melbourne in 1988 to take up a position at the Baker Medical Research Institute. He is a FRACP and FRCP.
Professor Dart was in receipt of both personal (Senior Principal Research Fellow) and direct research costs from the NHMRC from 1988 to 2017. Professor Dart was previously Acting Director (2002-2004) and Director (2004-2017) of the department of Cardiovascular Medicine at The Alfred.
Professor Dart's clinical interests, in addition to general cardiology, include hyperlipidaemia and control of cardiac risk factors. Research interests also include hyperlipidaemia and vascular function, particularly in relation to myocardial ischaemia and hypertension. He also has a major laboratory interest (Baker Institute) in myocardial ischaemia and infarction. Professor Dart has more than 300 publications related to cardiac disease.
Dr Denborough is a child and youth psychiatrist with more than 20 years experience.
Prof Christopher Fairley is Director of the Melbourne Sexual Health Centre and Professor of Public Health at Monash University.
He holds three specialist medical fellowships from the College of Physicians (Infectious Diseases), Faculty of Public Health and Chapter of Sexual Health Medicine. He is an editor of the Journal ‘Sexual Health’. His principle research interests are the public health control of sexually transmitted diseases and the effectiveness of clinical services. He has supervised 27 doctoral students to completion. He has 543 review journal publications and sits on the boards of IUSTI and ISSTDR.
Dr Andrew Gleason is a neuropsychiatrist and psychogeriatrician (old age psychiatrist) with a strong interest in cognitive disorders.
He runs a clinical trials unit at the Monash Alfred Psychiatry Research Centre specialising in new therapies for neurodegenerative disorders such as Alzheimer’s disease.
He was awarded Membership of the Melbourne Medical School Academy of Teachers for his contributions to medical education and is an author of A Primer of Clinical Psychiatry.
Mark qualified in Medicine at Melbourne in 1995. Following specialist respiratory training, he undertook a fellowship in severe asthma at the Royal Brompton Hospital and National Heart & Lung Institute in London.
He received his PhD from Imperial College London and later completed a Masters in Evidence-Based Health Care at Oxford. Mark heads Allergy, Asthma & Clinical Immunology services at the Alfred Hospital, and holds research affiliations with both Melbourne and Monash Universities. His interests include difficult asthma, allergic disease, pleural medicine, and endo-bronchial ultrasound.
Prof Jennifer Hoy is the Director of HIV Medicine at The Alfred.
Prof Hoy has over 30 years’ experience in HIV clinical research and patient care, and established the Clinical Research Unit at The Alfred. Prior to this, she established and directed the Infectious Diseases Clinical Research Unit from 1988-2008, building it into an internationally recognized research program.
She has been Principal Investigator for over 175 clinical studies at The Alfred and has collaborated widely on investigator-initiated pathogenesis studies.
Prof Hoy has been co-principal investigator on five large studies investigating ARV therapy and bone loss, including the SMART and START studies on which she was the Principal Investigator for Australia.
Prof Hoy has been a productive member of the IAS-USA Antiretroviral Guidelines Panel since 2012. Her current research interests include the comorbidities associated with ageing and HIV, especially bone and cardiovascular disease, and finding better ways to prevent and manage them.
Most significant trial
The START international study recruited 4500 people globally and demonstrated that starting treatment for HIV infection soon after diagnosis provided survival benefits in addition to reduction in AIDS and non-AIDS diseases. The results of this trial provided the gold standard evidence to change all antiretroviral guidelines throughout the world in 2015.
A/Prof Martin Hunn works as a neurosurgeon at The Alfred.
His clinical areas of special interest include acoustic neuroma and other cerebellopontine angle tumours, awake resection of low grade glioma, surgery for cerebral aneurysms and arteriovenous malformations, cervical spine surgery and the surgical management of trigeminal neuralgia. A/Prof Hunn has an appointment with the Central Clinical School, Monash University. His primary research interest has been immunotherapy for primary brain tumours, but this is evolving to include the management of critically ill patients following traumatic brain injury with intracranial haemorrhage.
Peter Hunter is a geriatrician with 30 years of experience.
He was the inaugrual president of the Australian and New Zealand Society for Geriatric Medicine. He is the Chair of the Clinical Leadership Group for the Care of Older People. His interests include safety and quality in older people, innovative service development and improving end of life care.
Josh Ihle is an intensive care specialist and The Alfred’s clinical lead for the organ donation, and burns units.
Josh also manages the Alfred Critical Care Ultrasound course, as well as teaches several ICU courses at the hospital.
He has a keen interest in cardiothoracic intensive care, particularly Extracorporeal Membrane Oxygenation, echocardiography and organ donation.
Professor Kaye is the Director of Cardiology and a senior cardiologist in the Heart Failure & Transplant service at The Alfred.
Professor Kaye is an NHMRC Senior Principal Research Fellow and Head of the Cardiology Division at the Baker Heart and Diabetes Institute.
He is recognised internationally for his work on the pathophysiology of heart failure. His studies have identified a range of the fundamental mechanisms that contribute to the progressive nature of heart failure. He has published over 340 research articles, his H index is 77, with over 23,000 citations.
Professor Kaye holds numerous research grants including an NHMRC Program Grant (as leader), NHMRC Centre of Research Excellence Grant and an NHMRC Development Grant.
Prof Kaye’s research has also created a substantial portfolio of intellectual property related to the invention of novel medical devices. These have been the basis for the formation of three start-up companies, including Osprey Medical which was successfully listed on the ASX. All companies have advanced active clinical trial programs.
Prof Kaye is the recipient of the Eric Susman and RT Hall Prizes for research excellence from the College of Physicians and Cardiac Society. He was awarded the 2012 Eureka Prize for Medical Research Translation.
Most significant clinical trial
A novel formulation of a drug used to treat advanced heart failure, now tested in over 40 patients with severe symptoms.
Prof John Kelly is a consultant dermatologist at the Victorian Melanoma Service at The Alfred in Melbourne, a multidisciplinary treatment service for melanoma.
John founded the service in 1994 and headed the service until 2018. He is a dermatologist and holds the appointment of Adjunct Professor at the Monash University Department of Medicine at Alfred Health.
From 1987-2005, he also headed the Dermatology Unit at The Alfred. He undertook his Doctorate at the Melanoma Clinic, University of California, San Francisco on the subject of melanoma diagnosis and management.
He maintains an active program of research in melanoma diagnosis and is the author of many published papers on the subject. He has served on the boards of the Australia and New Zealand Melanoma Trials Group and Melanoma Research Victoria and is a steering committee member and author for the Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand.
He was awarded an AM in 2018 for “significant service to medicine through the management and treatment of melanoma, as a clinician and administrator and to education”. In 2018, he received, the Belisario Award for Academic Dermatology from the Australasian College of Dermatologists, in recognition of his contribution to melanoma research.
Professor Kistler is an international leader in the treatment of cardiac arrhythmia and related research.
He is Head of Electrophysiology at The Alfred and the Head of Clinical Electrophysiology Research at The Baker Heart and Diabetes Institute. He is also Professor of Medicine at the University of Melbourne.
Professor Kistler has completed a PhD and post-doctoral research at St Bartholomews Hospital, London and supervised 10 PhD students. He has been supported by the NHMRC and National Heart Foundation through fellowships and project grant support.
He is an invited speaker at the prestigious Heart Rhythm Society and American Heart Association in the USA and has more than 150 publications – many in the world’s leading cardiology journals.
Prof Kulkarni directs a large psychiatric research group, the Monash Alfred Psychiatry Research Centre (MAPrc).
MAPrc is dedicated to discovering new treatments, new understanding and new services for people with a range of mental illnesses.
Prof Kulkarni became a Fellow of the Royal Australian and New Zealand College of Psychiatrists in 1989 and was awarded a PhD from Monash University in 1997 for her thesis “Women and Psychosis”. She is internationally acknowledged as a leader in the field of reproductive hormones and their impact on mental health. Prof Kulkarni was elected the President of the International Association of Women’s Mental Health in 2017.
Most significant trial
Pioneering the use of Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.
Natasha is an occupational therapist who holds appointments with several institutions.
Natasha holds a joint appointment with La Trobe University (School of Allied Health) and honorary appointments at the John Walsh Institute for Rehabilitation Research at The University of Sydney, the George Institute for Global Health and the Florey Neurosciences at The University of Melbourne. Working within the Alfred Health hospital network, she conducts clinical trials investigating the effectiveness of rehabilitation interventions, as well as translation research into improving the long-term outcomes for those living with brain injury from stroke or traumatic causes. She has published widely in leading journals such as Stroke, Journal of Epidemiology, and Clinical Rehabilitation, and has received competitive research grants from federal government (including NHMRC), state government (includingthe Transport Accident Commission) and philanthropic organisations (including the National Stroke Foundation).
A/Prof Victoria Mar is the Director of the Victorian Melanoma Service at The Alfred and Adjunct Associate Professor at the School of Public Health and Preventive Medicine, Monash University.
She completed her PhD at Monash University/VMS and Peter MacCallum entitled ‘Clinical and molecular characteristics of aggressive melanoma’ (2014), and supervises doctoral students in clinical and translational research projects.
She is a board member of the Australian and New Zealand Melanoma Trials Group and the Skin and Cancer Foundation. She has authored and co-authored a number of chapters for the Cancer Council Australia Melanoma Guidelines and is Clinical Lead for the Melanoma Clinical Outcomes Registry.
A/Prof Silvana Marasco is a Cardiothoracic Surgeon at both The Alfred and Epworth hospitals in Melbourne, Australia.
She is currently the Deputy Director of the CJOB Cardiothoracic Unit at The Alfred. A/Prof Marasco performs the full spectrum of adult cardiac and thoracic operations, including heart and lung transplants and implantation of mechanical assist devices. Her surgical areas of interest include minimally invasive valve surgery, innovative techniques, and management of chest trauma. She has a Master of Surgery, Master of Bioethics, a PhD and has published over 100 peer reviewed journal articles and 10 book chapters. Her research interests have focussed on chest trauma, transplantation outcomes and innovations in surgical techniques for which she has received over $6million in total funding.
Assoc Prof Steve McGloughlin completed his training in intensive care in a combination of metropolitan and rural centres before coming to the Alfred in 2011.
He is passionate about the delivery of quality, compassionate care to critically ill patients and providing support for staff who work in this difficult area. His clinical areas of interest include infections in the critically ill, ECMO and communication skills. He previously worked for the Royal Flying Doctor Service in remote Australia.
Rob Melvin is an emergency physician at Alfred Health, working in the Emergency and Trauma Centre at The Alfred, and the Emergency Department at Sandringham Hospital.
His clinical areas of special interest include team leadership in resuscitation, paediatrics in the emergency department and infectious diseases in the emergency department setting.
Prof Biswadev Mitra works as an Emergency Physician at Alfred Health.
His clinical areas of special interest include trauma resuscitation, traumatic brain injury, blood and blood product usage during trauma resuscitation. Prof Mitra has an appointment with the School of Public Health and Preventive Medicine, Monash University.
His primary research interest has been in blood transfusion and clotting disorders during trauma resuscitation and traumatic brain injury.
Paul Myles is an anaesthetist with a special interest in cardiac and trauma anaesthesia, patient safety, awareness (“waking up” during surgery), and research methods to measure patient quality of recovery.
He was the founding Chair of the ANZCA Clinical Trials Group, is an Australian National Health and Medical Research Council Practitioner Fellow, and a Fellow of the Australian Academy of Health and Medical Science.
Prof O'Brien is the Program Director for Alfred Brain and Director of Neurology at The Alfred.
Prof O'Brien is a specialist in neurology and clinical pharmacology, with particular expertise in epilepsy and related brain diseases, including traumatic brain injury, brain tumours and neurodegenerative diseases, neuropharmacology and in-vivo imaging in animal models and humans.
He was formerly The University of Melbourne’s James Stewart Chair of Medicine and Head of the Department of Medicine at the Royal Melbourne Hospital (2008-17).
He leads a large translational research team focused on improving treatments for people with epilepsy and related brain diseases. Prof O’Brien’s research has two primary goals:
- to better understand the determinants of treatment response, identify biomarkers for treatment outcomes, and develop new treatment approaches.
- to investigate the fundamental neurobiological basis, and inter-relationship, of the neuropsychiatric co-morbidities present in many patients with epilepsy and neurodegenerative conditions.
He has been a Principal Investigator in more than 100 commercially sponsored and investigator initiated trials, and is Chair of the Australian Epilepsy Clinical Trial Network (AECTN). He published more than 395 peer-reviewed original papers in leading scientific and medical journals which have been cited around 14,000 times.
Most significant trial
The STAR 1 trial (2016-18), for which Prof O’Brien was the Principal Investigator, was the first double-blinded randomised control trial of a cannaboid treatment for adults with drug resistant focal epilepsy. It was also the first to trial a novel transcutaneous delivery system that avoided many of pharmacokinetic and side-effects issues with oral cannaboid treatments. The study involved 188 participants and 14 trial sites across Australia and New Zealand, coordinated by the AECTN which Prof O’Brien chairs. The results of the study showed that the treatment was well tolerated, with excellent patient compliance and acceptance, establishing the viability of the transdermal treatment approach. Continued open-labelled treatment in STAR 2 showed sustained clinically meaningful reductions after 6 & 12 months of treatment.
Professor Robyn O’Hehir is known internationally for her innovative research in allergy and respiratory medicine.
For the past ten years she has headed Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University, the first University in Australia to establish a Chair of Allergy and Clinical Immunology. Professor O’Hehir has been a key figure in advocacy, policy development and community service for those affected by respiratory allergy, asthma and cystic fibrosis in Australia. She served as State President of the Australasian Society for Clinical Immunology and Allergy, as well as a non-executive Director on the Board of Cabrini Health and a member of the Menzies Foundation Council. She is honoured to be an Officer of the Order of Australia, a Fellow of the Thoracic Society of Australia and New Zealand, a Fellow of the Australian Academy of Health and Medical Science and a Life Governor of Asthma Victoria.
Dr Palit is a Rehabilitation Physician with a strong interest in Neurological Rehabilitation.
Previously Headed the Neurological Rehabilitation Stream at Caulfield Hospital. Research interest in Spasticity Management. Part of the team responsible for developing the Model of Care for the Alfred ABI Rehabilitation Centre and has gone on to become the Clinical Lead for this new rehabilitation Service
Anton is a Professor of Infectious Diseases and Microbiology, and is the Director of the Department of Infectious Diseases at The Alfred Hospital and Central Clinical School, Monash University.
He completed his infectious diseases clinical training in Australia in 2005 and then went to the USA for four years and worked at the Harvard-affiliated hospitals: Beth Israel Deaconess Medical Center and Massachusetts General Hospital. He completed a Masters of Public Health at Harvard School of Public Health, and also completed a PhD in Infectious Diseases and Microbiology. His research interests are in hospital-acquired infections, antibiotic resistance, mechanisms of pathogenesis and infections in immunocompromised hosts.
He is also an active clinician working in the area of hospital-acquired infections and transplant infectious diseases. He is a committee member of the Clinical Research Network of the Australasian Society of Infectious Diseases and the Taskforce against Multidrug-resistant Gram-negative Bacteria for the Australian Commission on Safety and Quality in Healthcare. He has received numerous national and international awards for his advanced research and contribution to Infectious Diseases and Microbiology.
Prof Stuart Roberts is the Head of Hepatology and a consultant gastroenterologist at The Alfred.
Having completed a Hepatology Fellowship at the Mayo Clinic in the USA, Professor Roberts was awarded a Doctorate of Medicine by the University of Melbourne for his liver research.
More recently, he completed a Master of Public Health at Monash University with High Distinction.
His main research interests are hepatocellular carcinoma, viral hepatitis, autoimmune hepatitis, fatty liver disease, and non-invasive markers of liver disease.
He has been Principal Investigator in over 165 sponsored and investigator-initiated clinical trials from phase I-IV. Professor Roberts has published more than 170 original articles across a range of high-impact journals including the New England Journal of Medicine, Lancet, Annals of Internal Medicine, Gastroenterology, Gut, Hepatology, and Journal of Hepatology.
Most significant trial
The Phase III randomised controlled trial of Sofosbuvir and Velpatasvir in patients with chronic hepatitis C genotype 3 infection. This was published in the New England Journal of Medicine and is now the standard of care for the vast majority of patients with chronic hepatitis C.
Prof Jeffrey Rosenfeld is a Senior Neurosurgeon in the Department of Neurosurgery at The Alfred, and Director of the Monash Institute of Medical Engineering (MIME).
His research interests are on improving the outcome for patients with traumatic brain injury and restoring sight to blind individuals using bionic vision, a wireless electrode interface with the brain.
He is also a Fellow of the Australian Academy of Health and Medical Sciences, the Australian Academy Technological Sciences and Engineering, and an International Fellow of the American Association of Neurological Surgeons and the American College of Surgeons.
Prof Mark Shackleton is the Director of Oncology at The Alfred.
Prof Shackleton is also Professor of Oncology, Monash University, Victorian Cancer Agency Clinical Research Fellow and Chair, Australian and New Zealand Melanoma Trials Group.
After training in medical oncology at the Ludwig Institute in Melbourne, Prof Shackleton undertook PhD studies at the Walter and Eliza Hall Institute of Medical Research and post -doctoral work at the University of Michigan, USA.
He has consistently published in the world’s top medical and scientific journals.
Prof Shackleton has received several major prizes for his research, including the 2006 Victorian Premier’s Award for Medical Research, a 2010 NHMRC Achievement Award, a 2011 Pfizer Australia Fellowship, and a 2016 Victorian Cancer Agency Clinical Research Fellowship. In 2012, he was awarded the Australian Science Minister’s Prize for Life Scientist of the Year.
The Alfred Oncology Unit has been a key player internationally in conducting clinical trials, particularly in melanoma and brain cancer, contributing substantially to key findings published in leading journals such as the New England Journal of Medicine.
De Villiers is an Emergency Physician with a strong interest in clinical research, systems design, quality improvement and patient flow.
As Director of Emergency Services at Alfred Health and Director of The Alfred Emergency & Trauma Centre, de Villiers oversees the busiest trauma centre in Australasia. He has been instrumental in the development and implementation of several care models to improve the patient care and experience. He has previously worked in major trauma centres in South Africa, Hong Kong, the United Kingdom and New Zealand.
De Villiers is also Deputy Clinical Program Director, Emergency and Acute Medicine, Alfred Health, and Associate Professor at Monash University School of Public Health and Preventive Medicine.
Prof Andrew Spencer is the Head of our Malignant Haematology & Stem Cell Transplantation Service.
He completed his medical training in clinical and laboratory haematology in 1992. Subsequently, he was awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, where he undertook research into B-cell clonality in chronic myeloid Leukaemia under the supervision of Professors John Goldman and Junia Melo and was awarded a Doctorate of Medicine from the University of London.
Andrew moved to The Alfred in 1999 where he established an independent translational research program. In parallel he established a first-in-human and early phase haematology clinical research unit at The Alfred and was appointed Head of the Malignant Haematology & Stem Cell Transplantation Service in 2007.
Most significant trial
The ALLG MM17 trial for myeloma patients who fail to respond to standard treatment. This group of patients has historically had poor survival rates. Professor Spencer’s approach exploring the use of Kyprolis and thalidomide has demonstrated very high response rates, including patients becoming minimal residual disease (MRD) negative.
Find out more about Andrew's research interests.
Simon has been a psychiatrist in the private and public sectors for over 25 years.
As the Program Director of Psychiatry at Alfred Health, Simon is responsible for the delivery of specialist and primary mental health services in the inner south of metropolitan Melbourne, and a psychiatry research centre in partnership with Monash University, known as MAPrc (Monash-Alfred Psychiatry Research Centre). As the lead agency for headspace Elsternwick since 2009 and the headspace Youth Early Psychosis Program in South-East Melbourne since 2013, the program has led a consortium of agencies in developing a youth mental health service that has been co-designed with carers and young people, and is delivered in primary care settings. He is an active member of the Royal Australian and New Zealand College of Psychiatrists and has consulted to a number of state and commonwealth advisory committees. In 2016, he will be undertaking the Williamson Community Leadership Program, run by Leadership Victoria.
Mr Jin Tee is a complex spine and brain surgeon. His surgical practice focuses on minimally invasive (MIS) and open surgical solutions for degenerative spinal disorders (including pars defect repairs), spinal tumours, spinal deformity including scoliosis, cranio-cervical junction abnormalities, and spine trauma. He also treats brain trauma, tumours, and brain fluid (CSF) flow dysfunction.
Mr Tee is heavily involved in clinical research. He concentrates on clinical outcomes of spine surgery in the fields of spine trauma, degenerative spine and spine oncology. He is involved in registry-based studies in Australia and North America to ultimately assist in improving the international quality of spine care. He is also involved internationally in spinal cord and spine column injury research. He is an active research member of the AO Spine International Oncology Study Group and a clinical researcher at the National Trauma Research Institute (NTRI). He is part of the medical advisory group (Monash Vision Group) for the Bionic Eye project in Melbourne.
Mr Tee was a medical graduate of the University of Melbourne and a Melbourne-based Australian Neurosurgery trainee. He has completed a post-graduate Doctorate of Medicine at Monash University (Melbourne). He then completed the AO Spine North America Complex Spine Surgery Fellowship at the world-renowned Vancouver Spine Institute, Vancouver General Hospital and the University of British Columbia.
Dr Tony Walton is Deputy Director and Head of Catheter Laboratory in the Department of Cardiology. He is a clinician, interventional cardiologist who specialises in structural heart procedures.
Tony is an interventional cardiologist based at The Alfred and is an Associate Professor in Medicine at Monash University. He is an Honorary Research Fellow at The Baker Institute as well as Head of the Structural Heart Programme at the The Alfred and Director of the Cardiac Interventional Laboratories at Western Health.
His training in cardiology was at The Alfred and further postgraduate training in interventional cardiology was undertaken at Stanford University Medical Centre in the United States.
His professional interests include general and interventional cardiology with particular interests in structural heart disease and hypertension. The developing areas of percutaneous valve replacement and interventional techniques for the treatment of common conditions such as hypertension are particular interests. He has published his clinical and research work in peer reviewed manuscripts on subjects including the novel techniques of percutaneous aortic valve replacement and renal denervation for refractory hypertension
A/Prof Andrew Wei is a haematologist and the head of leukaemia research at The Alfred.
A/Prof Wei is also Chairperson AML disease group Australasian Leukaemia and Lymphoma Group, Victorian Cancer Agency Research Fellow and Adjunct Associate Professor, Australian Centre for Blood Diseases.
After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, A/Prof Wei joined The Alfred in 2008 to develop the Acute Myeloid Leukaemia (AML) research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator.
A/Prof Wei is an executive member of the ALLG Scientific Advisory Committee, and a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia. He sits on the International Steering Committee for Celgene, providing expert advice on AML.
To enhance translational research, A/Prof Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.
Most significant trial
The Alfred has made a significant impact in positioning a new class of drugs called BH3- mimetics, designed to promote cancer cell death, to treat patients with AML. The Alfred has conducted a number of clinical trials (phase 1b-3) in collaboration with Abbvie which has resulted in highly promising outcomes for elderly patients with AML. Pivotal studies are now underway to determine whether venetoclax in combination with low-dose chemotherapy will become the new standard of care for elderly AML.